



Synchrony® Accommodating IOL Featured in Ten Podium Presentations at Annual Meeting of the American Society of Cataract and Refractive Surgeons

San Francisco, CA, April 14, 2009 – Clinical research outcomes of the Synchrony® dual optic accommodating intraocular lens (IOL) were featured in ten podium presentations, two posters, and one film at the annual meeting of the American Society of Cataract and Refractive Surgeons (ASCRS). The Synchrony IOL is not approved for commercial marketing in the U.S. and is available only through an Investigational Device Exemption study.

Highlights of the ASCRS presentations include:

- A presentation by Douglas Koch, M.D., demonstrating mechanism of accommodation and objective proof of accommodation at one and two years, which received the Best Paper of the Session award.
- A presentation by Professor Gerd Auffarth, M.D., of the University of Heidelberg, demonstrating objective proof of accommodation at five years.
- Long-term functional data presented by Victor Bohorquez, M.D., showing sustained distance-corrected near reading acuity and reading speed between one and two years.
- Data demonstrating continued low rates of posterior capsular opacification (PCO) including results presented by John Vukich, M.D., showing only four YAG capsulotomies in a population of 209 patients at two years.

- Results from a multicenter, double-masked, randomized trial comparing Synchrony(n=39) to the Alcon ReSTOR multifocal IOL(n=43), showing a statistically significant improvement in intermediate vision vs. ReSTOR, improved spectacle independence, and equivalent near and distance vision at twelve months.

“The breadth and depth of the clinical data presented here at ASCRS are clear evidence of Visiogen’s commitment to putting science first,” said Kevin Hykes, Chief Commercial Officer at Visiogen, Inc. “We look forward to continuing to work with physicians around the world to fully characterize the mechanism of accommodation and long-term performance characteristics of the Synchrony Accommodating IOL.”

These presentations add to the growing foundation of clinical evidence on the Synchrony lens, with over 1,000 clinical trial implants to date. Visiogen has completed its U.S. IDE study and will submit the results to the FDA in 2009, with PMA approval anticipated in 2010.

###

About Visiogen

Visiogen, Inc. is focused on developing innovative products for cataract and refractive patients. Founded in 2001 and located in Irvine, California, Visiogen’s first commercial application, the Synchrony®, a 3-dimensional dual optic accommodating intraocular lens and pre-loaded injector, is currently in the final phase of a U.S. IDE study, and was commercially released in Europe in 2009. More information about Visiogen and the Synchrony technology can be found at www.visiogen.com.

Additional facts about the company and its offerings can also be obtained by contacting:

Kate Jennings
Maricich Brand Communications for Visiogen, Inc.
Tel. 949-223-6455

Fax 949-223-6451
kate@maricich.com

Kevin Hykes
Chief Commercial Officer
Visiogen, Inc.
info@visiogen.com